ADMA Biologics, Inc. ADMA

Company Overview

ADMA Biologics, Inc. is a U.S.-based biopharmaceutical company focused on the development, manufacture, and commercialization of plasma-derived biologics for the treatment and prevention of infectious diseases and immune deficiencies. The company operates within the specialty biologics and plasma therapeutics industries, with its primary focus on immune globulin products derived from human plasma. ADMA’s core revenue drivers are its commercial immune globulin therapies and plasma collection operations, which support both internal manufacturing needs and external plasma sales. The company primarily serves hospitals, specialty pharmacies, infusion centers, physicians, and patients with compromised immune systems in the United States.

ADMA’s commercial portfolio includes products such as BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) therapies used for primary humoral immunodeficiency and related immune conditions. The company also operates a vertically integrated business model through its plasma collection subsidiary network, providing greater control over raw material supply and manufacturing economics. ADMA was founded in 2004 and evolved from a development-stage biotechnology company into a fully integrated commercial biologics manufacturer following acquisitions of manufacturing and plasma collection assets, including the acquisition of the Boca Raton manufacturing facility previously owned by Biotest Pharmaceuticals.